MedPath

Evaluation of Geistlich Fibro-Gide® in Comparison to CTG for the Treatment Around Implants

Not Applicable
Active, not recruiting
Conditions
Soft Tissue Defect
Interventions
Procedure: Soft tissue flap + Connective Tissue Graft
Device: Soft tissue flap + Geistlich Fibro-Gide®
Registration Number
NCT04703738
Lead Sponsor
Geistlich Pharma AG
Brief Summary

This double blind, randomized, parallel study evaluates the non-inferiority of Geistlich Fibro-Gide® in comparison to connective tissue graft for soft tissue volume augmentation around dental implants

Detailed Description

A total sample size of 60 subjects (n=60) will be evaluated at 5 centers, by 6 Investigators with approximately 10-subjects per Investigator. Power analysis based on 80% power, past Thoma, Zeltner and González-Martin studies 1,2,3 and a one-sided confidence interval of 0.025, indicates that with a volume change standard deviation between 0.5 and 0.7 mm, 17-31 subjects are required per group (test and control), so 50-60 subjects are an acceptable estimate, with a preference for 60, given potential loss to long-term follow-up.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
60
Inclusion Criteria
  • Subjects requiring soft tissue augmentation around single implants, i.e., thin biotype with potential for
  • All implants must be at least 6 months post bone graft/implant placement
  • have at least 1 mm of keratinized tissue width (KTw),
  • have final restoration permanently in place for at least 4-weeks and
  • subject have no recession on the implant body
  • Subjects who, can achieve good oral hygiene (80% plaque free surfaces on the implant and maintain 80% plaque free surfaces on teeth adjacent to treatment sites).
Exclusion Criteria
  • participation within the last six months in other interventional studies.
  • any systemic condition that could influence healing, such as uncontrolled diabetes mellitus - confirmed by A1C score ≥7% - cancer, HIV, oral muco- cutaneous conditions and drug induced gingival enlargement.
  • taking medications that compromise wound healing, such as chronic steroid use - either inhaler or systemic, calcium channel blockers with secondary hyperplastic tissue reactions, anti-seizure medications, IV bisphosphates for bone metabolic diseases, radiation or other immuno-suppressive therapy.
  • acute infectious lesions in the areas intended for surgery.
  • History within the last 6 months of weekly or more frequent use of nicotine products
  • Female subjects who are pregnant or lactating, or sexually active female subjects who are of childbearing potential and who are not using hormonal or barrier methods of birth control
  • Untreated, moderate to severe periodontal disease.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
ControlSoft tissue flap + Connective Tissue GraftSoft tissue flap + Connective Tissue Graft
TestSoft tissue flap + Geistlich Fibro-Gide®Soft tissue flap + Geistlich Fibro-Gide®
Primary Outcome Measures
NameTimeMethod
Change in gingival soft tissue volume assessed with 3D scanning6 months post treatment

Change in gingival soft tissue volume compared to baseline \[Time Frame 6 months post-treatment\] Measured by digital contour scan

Secondary Outcome Measures
NameTimeMethod
Post-OP Patient Reported Outcome Questionnaire6 Months, 1,3,5 Years

subjects will answer a questionnaire regarding discomfort, esthetic satisfaction and overall satisfaction questions asked by a 3rd-party rec

At Visits 2-weeks, and 1- and 3-months post-operative, subjects will answer discomfort/ pain questions asked by a 3rd-party recorder.

Concomitant medication2,4,12 weeks, 6 months, 1,3,5 Years

Concomitant medication review compared with Visit 1 and 2

All Adverse Events, serious and non seriousDay 0, after 2, 4, 12weeks, 6 Months, 1,3,5 Years

Recording and Assessment of all (S)AEs starting from Visit 2 onwards, Surgery

Change in gingival soft tissue contour3 months, 1,3, 5 Years

soft tissue contour measured digitally ( 3D-scan) and compared with baseline

General Periodontal Examination (GPE)4, 12 weeks, 6 Months, 1,3,5 Years

Changes of GPE at various visits compared to baseline,

Pink esthetic score (PES)6 Months, 1,3,5 Years

pink esthetic score evaluates soft tissue around single-tooth implants. The PES is based on seven variables: Mesial papilla, Distal papilla, Soft tissue Level, Soft-tissue contour, Alveolar process deficiency, Soft-tissue Color, Soft tissue texture, 2-1-0 score

Trial Locations

Locations (5)

Regenerative Solutions

🇺🇸

Fullerton, California, United States

Periodontal and Dental Implant Surgical Specialist

🇺🇸

Virginia Beach, Virginia, United States

Santarelli Oral and Facial Surgery

🇺🇸

Kenosha, Wisconsin, United States

McClain Schallhorn Periodonitcs

🇺🇸

Aurora, Colorado, United States

Perio Health Professionals

🇺🇸

Houston, Texas, United States

© Copyright 2025. All Rights Reserved by MedPath